Skip to main content
Press release November 3, 2026

Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026

Relmada Therapeutics, Inc. (RLMD)

November 03, 2026 07:00 ET CORAL GABLES, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) — Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, November 12, 2026 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2026, and recent business progress. Conference Call and Webcast Information: Date: Thursday, November 12, 2026 at 4:30 PM ET Participant Dial-in (US): 1-800-717-1738 Participant Dial-in (International): 1-646-307-1865 Webcast Access: Click Here A replay of the webcast will be available in the Investors section of the Relmada website at https://ir.relmada.com/investors/events/. About Relmada Therapeutics, Inc. Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through clinical development with the potential to address significant unmet needs. For more information, visit www.relmada.com Investor Contact: Brian Ritchie LifeSci Advisors britchie@lifesciadvisors.com Media Inquiries: Corporate Communications media@relmada.com
View original release